Skip to main content
. 2017 Jun 20;35(28):3181–3188. doi: 10.1200/JCO.2017.72.4138

Fig 4.

Fig 4.

Greatest prostate-specific antigen (PSA) change from baseline at any time on study according to mean percent androgen receptor nuclear localization (%ARNL) at cycle 1 day 8 (C1D8; after 1 week of therapy). (A) Comparison of the lower three quartiles versus the upper quartile of mean %ARNL at C1D8 (n = 31); PSA ≥ 50% decrease from baseline was more common in patients with %ARNL in the lower three quartiles (71%) than in patients with %ARNL in the upper quartile (29%). (B) Comparison of increase versus decrease in %ARNL from cycle 1 day 1 (C1D1) to C1D8 (n = 25); PSA change from baseline was 40% in patients with increased mean %ARNL compared with 67% in patients with decreased mean %ARNL. Thirty-one patients had PSA change and evaluable circulating tumor cells (CTCs) at C1D8; 25 patients had PSA change and evaluable CTCs at both C1D1 and C1D8.